Blinklab Limited · ASX:BB1
Blinklab — TechKnow Invest Roadshow Conference 2025
27 slides from Blinklab's conference presentation, Aug 19, 2025
Slide 1: BlinkLab Presenting This Week at the TechKnow Invest Roadshow Conference
19 August 2025 BlinkLab Presenting This Week at the TechKnow Invest Roadshow Conference BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), a leading digital healthcare innovator, is pleased to announce that it will be presenting at the TechKnow Invest Roadshow conference this week in both Me
Slide 2: About BlinkLab Limited
About BlinkLab Limited BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagn
Slide 3: Early and Accurate Diagnosis of Autism and ADHD
(ASX:BB1) For personal use only Early and Accurate Diagnosis of Autism and ADHD Introducing an AI-powered smartphone platform for neurological testing August 2025 Brian Leedman, Chairman 1
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about For personal use only BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 5: Corporate Snapshot
Corporate Snapshot Next-Generation Digital Solutions for Neurodevelopmental Health For personal use only CAPITAL STRUCTURE ASX Code BB1 Shares on Issue 125M Options on Issue 44M Founders’/ Directors’ percentage 24% Market Cap (30 July 2025) $55.7M Cash (30 June 2025) $8.7M Henk-Jan Boele, Anton Uvar
Slide 6: What is Autism?
What is Autism? Neurodevelopmental condition For personal use only that affects how the brain processes sensory information. Autism can impact: • Social development • Language development • Sensory processing • Behavior and interests August 2025 I www.blinklab.org 4
Slide 7: Economic Burden of Autism in USA: $700B in 2024
Economic Burden of Autism in USA: $700B in 2024 "The economic burden is significant and alarming” 1 For personal use only Prevalence has grown up to 2-4% among children2 Autism healthcare expenses are soaring3 • Costs for an autism diagnostic evaluation: $1,000 to $7,000 • Lifetime cost for individu
Slide 8: NDIS Payments for Autism in Australia: A$8.4B in 2024
NDIS Payments for Autism in Australia: A$8.4B in 2024 NDIS payments for autism rise by more than 20% annually, with the largest share allocated to Supervised Independent Living (SIL). For personal use only Data extracted and visualized by BlinkLab. Extracted from National Disability Insurance Scheme
Slide 9: Early diagnosis and intervention enhance independent living skills
Consensus: Early diagnosis and intervention enhance independent living skills in people with autism. For personal use only Recommendation by they American Academy of Pediatrics: “All children must be screened for autism at ages 18 and 24 months” Market size = Total number of children born each year:
Slide 10: Sources
For personal use only Sources: Left up - The Australian 15 February 2014; Right down- Sydney University 6 February 2023, www.sydney.edu.au/brain-mind; August 2025 I www.blinklab.org 8
Slide 11: Autism diagnosis is expensive, inefficient, and often late
Autism diagnosis is expensive, inefficient, and often late The costly labor and time-intensive diagnostic evaluations are unnecessary for many children. 3-5 years of uncertainty for family and child For personal use only ? ? Occupational Parents Primary Care Neuro- Late autism Late Concerned or GP P
Slide 12: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis The costly labor and time-intensive diagnostic evaluations are unnecessary for many children. For personal use only Diagnosis in weeks to months ? ? Parents Primary Care Neuro- Early autism Early and personalized intervention Concerned or GP
Slide 13: Our patented solution: Neuroscience on a smartphone
Our patented solution: Neuroscience on a smartphone Minuscule facial reflexes, evoked by our Evokes Facial Reflexes For personal use only app, generate a digital biomarker for autism. By presenting visual and auditory stimuli during smartphone use. Computer Vision Facial features are tracked on the
Slide 14: Beyond blinks: Tracking of vocal responses and hand/head movements
Beyond blinks: Tracking of vocal responses and hand/head movements as objective markers for autism For personal use only 12 Image used with permission of child and caregiver
Slide 15: Large Study Validates and Enhances BlinkLab's Accuracy in Detecting Autism
Large Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children1 For personal use only Released on 19 November 2024 In a sample of 441 children, BlinkLab achieved a sensitivity of 91% and specificity of 85% 1) ASX Announcement (19 November 2024) - Large-Scale Study Validates a
Slide 16: BlinkLab Outperforms FDA-approved Digital Peers
BlinkLab Outperforms FDA-approved Digital Peers We are leaders in the digital diagnostics and therapeutics space For personal use only Sensitivity 91% 52%* 71% Specificity 85% 19%* 81% Smartphone-based Ye Ye No s s FDA approval No - 510(k) Yes - De Novo Yes - 510(k) * Calculated over all study compl
Slide 17: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD For personal use only BlinkLab precisely measures sensory sensitivity in people with autism and ADHD. 15
Slide 18: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Real-time drug monitoring offers a path to even larger recurring revenues via subscription-based models. 16
Slide 19: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist a
Slide 20: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and
Slide 21: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. For personal use only BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and p
Slide 22: Progress and structure of the US FDA study
Discuss the progress and the structure of the US FDA study. What is the timing of the US FDA study? Q4 2024 - CRO assigned* 510(k) Trial: Prospective, multicenter, double- - IRB approval for initial 100-patient study* For personal use only blinded, within-subject comparison study - Pre-submission me
Slide 23: What learnings are expected from the FDA Pilot Study?
What learnings are expected from the FDA Pilot Study? For personal use only ● Final validation of BlinkLab Dx 1 in a ‘real-FDA-study-situation’ (proposed announcement in Q3 2025) ● Optimize SOPs for clinicians and families - protocols ● Optimize recruitment strategies ● Evaluate and optimize usabili
Slide 24: What is the minimum level of accuracy - sensitivity & specificity?
What is the minimum level of accuracy - sensitivity & specificity? Which is more important? What has been achieved to date? • For FDA approval, minimum requirement for both is 65% For personal use only • From clinical perspective, specificity is more important. Current questionnaire screeners aim fo
Slide 25: Why is there a difference between diagnosing autism in adults and in children?
Why is there a difference between diagnosing autism in adults and in children? Children Adults For personal use only Self-report, limited external Observation Source Parents, teachers, clinicians observation Tools Used ADOS, M-CHAT, Vineland Limited, AQ, RAADS-R, interviews Symptom Presentation More
Slide 26: Other applications for the technology and other trials underway
Discuss other applications for the technology and other trials underway. European ADHD Study1 For personal use only ○ Collaborator: Mental Care Group ○ Goal: Develop BlinkLab Dx 2 ADHD Model ○ Status: Recruiting. Recently expanded from 1 to 5 ADHD clinical sites, 300 children will have completed all
Slide 27: Contact
ASX:BB1 For personal use only Henk-Jan Boele (MD, PhD) Brian Leedman Co-founder and CEO Non-Executive Chairman brian@blinklab.org henkjan@blinklab.org M: +61 (0) 412 281 780 M: +31 (0) 611 132 247 info@blinklab.org @BlinkLab.App @Blink_Lab BlinkLab Limited (ASX:BB1) @BlinkLab Ltd @BlinkLab2193 25 ww